摘要
目的:探讨重组组织型纤溶酶原激活剂(rt-PA)静脉溶栓治疗急性脑梗死(ACI)的疗效及安全性,以及对血清S100B蛋白的影响。方法:将发病<4.5h的ACI患者68例分为rt-PA组与对照组;对照组给予常规治疗,rt-PA组在常规治疗基础上给予rt-PA静脉溶栓治疗。检测68例ACI患者入院时及治疗后3、7、14d血清S100B蛋白水平和10例健康体检者(正常组)空腹血清S100B蛋白水平。分别于治疗前及治疗后90d,采用中国脑卒中临床神经功能缺损评分量表(CSS)及Barthel指数(BI)对患者进行评定,对比两组的疗效,并评价安全性。结果:入院时血清S100B蛋白水平比较,rt-PA组和对照组较正常组明显增高(P<0.01),rt-PA组和对照组比较差异无统计学意义(P>0.05),治疗3、7、14d后,rt-PA组和对照组血清S100B蛋白水平逐渐降低,且均较治疗前明显降低(P<0.01),rt-PA组降低更明显(P<0.01)。CSS评分和BI比较,治疗前rt-PA组与对照组比较差异无统计学意义(P>0.05),治疗后rt-PA组较对照组改善更明显,比较差异有统计学意义(P<0.01)。两组出血并发症发生率比较差异无统计学意义。结论:ACI发病4.5h内给予rt-PA静脉溶栓能显著降低血清S100B蛋白水平,治疗有效、安全。
Objective:To investigate the efficacy and safety of recombinant tissue-type plasminogen activator ( rt-PA ) in acute cerebral infarction ( ACI ), and the effect to S100B Protein.Method:64 ACI patients ( stroke onset within 4.5 h ) were randomized into rt-PA and control groups.The control group were treated with conventional therapy, and the rt-PA group with additional rt-PA besides conventional therapy.The S100B Protein level were measured in 64 ACI patients on admission and 3, 7, 14 days after treatment and in 10 healthy patients ( normal group ) .The Chinese Stroke Scale ( CSS ) and the Barthel Index ( BI ) were used to evaluate the neurological functions before and 90 days after treatment.Result:On admission, the S100B Protein level in rt-PA and control groups were significantly higher than in normal group ( P〈0.01 ), there was no significant difference between the rt-PA and control group ( P〉0.05 ), the S100B Protein level was significantly lower 3, 7, 14 days after treatment in both groups ( P〈0.01 ), and it was significantly lower in rt-PA group than in control group ( P〈0.01 ) .CSS scores and BI of the rt-PA group and the control group showed no significant difference before treatment ( P〉0.05 ) and were significantly different after treatment ( P〈0.01 ) .The bleeding complication rate was no significant different in two groups ( P〉0.05 ) .Conclusion:Intravenous rt-PA thrombolysis within 4.5 h from onset can significantly reduce S100B Protein level and is effective and safe in ACI patients.
出处
《中国医学创新》
CAS
2012年第35期5-7,共3页
Medical Innovation of China
关键词
脑梗死
静脉溶栓
重组组织型纤溶酶原激活剂
S100B蛋白
Cerebral infarction
Intravenous thrombolysis
Recombinant tissue-type plasminogen activator
S100B Protein